studies

lung cancer : non small cell (NSCLC), ... vs. VEGF(R) inhibitor, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsATLAS, 2013 0.92 [0.70; 1.21] 0.92[0.70; 1.21]ATLAS, 201310%743NAnot evaluable progression or deaths (PFS)detailed resultsATLAS, 2013 0.71 [0.58; 0.86] 0.71[0.58; 0.86]ATLAS, 201310%743NAnot evaluable AE (any grade)detailed resultsATLAS, 2013 3.87 [2.10; 7.15] 3.87[2.10; 7.15]ATLAS, 201310%735NAnot evaluable AE (grade 3-4)detailed resultsATLAS, 2013 1.74 [1.29; 2.35] 1.74[1.29; 2.35]ATLAS, 201310%735NAnot evaluable AE leading to death (grade 5)detailed resultsATLAS, 2013 1.62 [0.52; 4.99] 1.62[0.52; 4.99]ATLAS, 201310%735NAnot evaluable0.510.01.0relative treatment effectwww.metaEvidence.org2024-07-03 14:12 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334 - treatments: 909